Recently, FASN, an enzyme that regulates the de novo synthesis of fatty acids, was shown to bind to and upregulate HIF-1α and its downstream target SLC7A11 to inhibit HCC ferroptosis and promote sorafenib resistance 95. The gene discussed is HIF1A; the disease is hepatocellular carcinoma.